Patient-reported Impact of ≥75% Increase in Good Days/Month on Migraine Symptoms, Quality of Life, and Brain Fog: Real-world Study of Adults With Chronic Migraine Treated With Eptinezumab
Charles Argoff1, Steven Herzog2, Ryan Smith3, Seema Soni-Brahmbhatt4, Susanne Awad5, S. Wald Grossman4, Foram Patel4, Fawad A. Khan6
1Albany Medical Center, 2Texas Neurology, 3St Lukes Health System, 4Lundbeck LLC, 5H. Lundbeck A/S, 6The McCasland Family Comprehensive Headache Center, Ochsner Neurosciences Institute; University of Queensland-Ochsner Clinical School
Objective:
This post-hoc analysis examined the impact of ≥75% increase in self-reported good days/month on migraine symptoms, quality of life (QoL), and brain fog in patients treated with eptinezumab from REVIEW, a real-world evidence study.
Background:
Eptinezumab, a monoclonal antibody that binds to the calcitonin gene-related peptide, is indicated for migraine prevention in adults. In REVIEW, patients reported an increase in good days and satisfaction with eptinezumab treatment.
Design/Methods:
REVIEW was an observational, survey-based, multisite US-based study. Patients were ≥18 years old, had a chronic migraine diagnosis, and had completed ≥2 consecutive eptinezumab infusion cycles. This post-hoc analysis evaluated the impact of eptinezumab treatment on symptoms, QoL, and brain fog in subgroups defined by ≥75% or <75% increase in self-reported good days/month after starting treatment.
Results:
Of 94 REVIEW participants, 92 had complete data for good days/month and were included in this analysis; 64.1% (n=59) reported ≥75% increase in good days/month, whereas 35.9% (n=33) reported <75% increase. A greater percentage of patients with ≥75% increase in good days/month reported satisfaction with eptinezumab’s impact on migraine symptoms (67.8%-89.8%) versus patients with <75% increase (27.3%-60.6%). For patients with ≥75% increase in good days/month, 78.0% reported higher satisfaction with their overall well-being after starting eptinezumab compared with 18.2% of patients with <75% increase. Prior to eptinezumab treatment, the prevalence of brain fog was similar across treatment subgroups (≥75% increase, 79.7%; <75% increase, 78.8%), but the proportion of patients who reported moderate to complete improvement in brain fog after eptinezumab treatment was higher in the ≥75% increase subgroup (76.6% vs 42.3%).
Conclusions:
A ≥75% increase in good days/month following eptinezumab initiation was associated with patient-reported improvements in migraine symptoms, overall well-being, and brain fog supporting the use of good days/month as an indicator of the comprehensiveness and effectiveness of migraine preventive treatment.
Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff.